Study participants receiving apomorphine also gave their treatment higher effectiveness scores than those who received the placebo.
Browsing: Cognitive/neurodegenerative disorders
Two anticancer and antidepressant drugs have been found to block a translational repression pathway that has previously been linked to neurodegeneration.
Researchers have developed computer models to further understanding the behavior of protein fragments and fibril aggregation in Huntington’s disease development.
In this review, the authors discuss the history of DBS for Parkinson’s disease, as well as outcomes, recent advances, and where the field will go next.
The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for Parkinson’s disease.
Curt Freed discusses his pioneering work on transplanting human fetal dopaminergic cells, and where Parkinson’s disease research and treatment is heading in the next decade.
The randomized, placebo-controlled Phase I-II clinical study will investigate CDNF delivered with Renishaw’s chronic drug delivery system in Parkinson’s disease patients.
Reducing mouse model brain levels of the protein Ephexin5 prevented the loss of excitatory synapses that typically leads to memory loss in Alzheimer’s disease.
This research article presents the first-in-man data demonstrating a relationship between changes in cognition and β2M. The phenomenon was reversible, which indicates its therapeutic potential.
A team of UK-based researchers has been awarded a major grant to investigate the relationship between alterations in the gut microbiota & neurodegenerative disorders.